Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Ever since the AIDS Drug Assistance Program (ADAP) faced the challenge of funding highly active antiretroviral treatment (HAART) in the late 1990s, there have been annual funding problems that resulted in some states capping enrollment, restricting drug formularies, and putting some HIV-positive clients on waiting lists.

ADAP woes deepen as budgets worsen and longevity improves